Publications
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine, First Faculty of Medicine
- Analysis of the Group of Pediatric Patients With Relapsing-Remitting Multiple Sclerosis: Data From the Czech National Registry2022 | Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Multiple sclerosis patient suitable for the treatment with ofatumumab2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Treatment persistence to ocrelizumab and local experience2021 | Faculty of Medicine in Hradec Králové
- Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis2021 | Faculty of Medicine in Hradec Králové
- Profile of a patient treated with siponimod in routine clinical practice2021 | Faculty of Medicine in Hradec Králové
Loading network view...